| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Neoplasms | 26 | 2022 | 760 | 3.610 |
Why?
|
| Bone Neoplasms | 22 | 2023 | 2529 | 1.350 |
Why?
|
| Drug-Eluting Stents | 5 | 2021 | 753 | 0.900 |
Why?
|
| Cardiovascular Agents | 4 | 2021 | 850 | 0.840 |
Why?
|
| Sirolimus | 6 | 2021 | 1564 | 0.840 |
Why?
|
| Spinal Cord Compression | 3 | 2019 | 235 | 0.810 |
Why?
|
| Peripheral Arterial Disease | 8 | 2022 | 1188 | 0.770 |
Why?
|
| Fractures, Spontaneous | 6 | 2019 | 230 | 0.670 |
Why?
|
| Epidural Abscess | 3 | 2023 | 84 | 0.540 |
Why?
|
| Absorbable Implants | 4 | 2021 | 342 | 0.510 |
Why?
|
| Coronary Restenosis | 3 | 2022 | 424 | 0.480 |
Why?
|
| Postoperative Complications | 15 | 2021 | 15295 | 0.470 |
Why?
|
| Angioplasty, Balloon | 3 | 2022 | 653 | 0.440 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2023 | 1363 | 0.420 |
Why?
|
| Paclitaxel | 1 | 2019 | 1708 | 0.400 |
Why?
|
| Spinal Fusion | 2 | 2019 | 1241 | 0.380 |
Why?
|
| Limb Salvage | 2 | 2011 | 433 | 0.360 |
Why?
|
| Sarcoma | 5 | 2018 | 1897 | 0.350 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 6487 | 0.340 |
Why?
|
| Stents | 2 | 2019 | 3280 | 0.340 |
Why?
|
| Quality of Life | 7 | 2022 | 12804 | 0.340 |
Why?
|
| Femoral Artery | 4 | 2022 | 845 | 0.330 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 1288 | 0.330 |
Why?
|
| Chondrosarcoma | 2 | 2020 | 309 | 0.300 |
Why?
|
| Femoral Neoplasms | 2 | 2017 | 77 | 0.290 |
Why?
|
| Models, Molecular | 15 | 2008 | 5456 | 0.280 |
Why?
|
| Retrospective Studies | 39 | 2023 | 77449 | 0.260 |
Why?
|
| Salvage Therapy | 1 | 2011 | 1275 | 0.250 |
Why?
|
| Walking | 3 | 2022 | 1180 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 380 | 0.230 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2023 | 67 | 0.230 |
Why?
|
| Treatment Outcome | 27 | 2023 | 63114 | 0.230 |
Why?
|
| Atherectomy, Coronary | 1 | 2022 | 148 | 0.220 |
Why?
|
| Middle Aged | 53 | 2021 | 213383 | 0.210 |
Why?
|
| Palliative Care | 1 | 2017 | 3493 | 0.210 |
Why?
|
| Antiviral Agents | 7 | 2008 | 2987 | 0.210 |
Why?
|
| Extremities | 4 | 2023 | 865 | 0.210 |
Why?
|
| Molecular Weight | 2 | 2021 | 2255 | 0.200 |
Why?
|
| Spinal Fractures | 2 | 2019 | 696 | 0.200 |
Why?
|
| Spine | 5 | 2020 | 1144 | 0.200 |
Why?
|
| Humans | 94 | 2023 | 744343 | 0.200 |
Why?
|
| Hypoalbuminemia | 1 | 2021 | 87 | 0.190 |
Why?
|
| Algorithms | 7 | 2023 | 13881 | 0.190 |
Why?
|
| Liposarcoma | 1 | 2023 | 333 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 9239 | 0.180 |
Why?
|
| Aged | 44 | 2021 | 163280 | 0.180 |
Why?
|
| Neurosurgical Procedures | 4 | 2019 | 2002 | 0.180 |
Why?
|
| Intermittent Claudication | 2 | 2012 | 309 | 0.180 |
Why?
|
| Flaviviridae | 3 | 2008 | 9 | 0.180 |
Why?
|
| Prosthesis Design | 3 | 2021 | 2110 | 0.180 |
Why?
|
| Fracture Fixation, Internal | 2 | 2016 | 917 | 0.170 |
Why?
|
| Lower Extremity | 5 | 2012 | 1158 | 0.170 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2020 | 118 | 0.170 |
Why?
|
| Prospective Studies | 15 | 2022 | 53288 | 0.170 |
Why?
|
| Cervical Atlas | 1 | 2018 | 21 | 0.160 |
Why?
|
| Lordosis | 1 | 2019 | 84 | 0.160 |
Why?
|
| Atherectomy | 2 | 2021 | 47 | 0.160 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 110 | 0.160 |
Why?
|
| Iliac Artery | 1 | 2020 | 364 | 0.160 |
Why?
|
| Male | 55 | 2021 | 350118 | 0.160 |
Why?
|
| Chondroblastoma | 1 | 2018 | 50 | 0.160 |
Why?
|
| Popliteal Artery | 2 | 2021 | 317 | 0.160 |
Why?
|
| Bone Diseases | 1 | 2021 | 416 | 0.150 |
Why?
|
| Mutation, Missense | 2 | 2006 | 2564 | 0.150 |
Why?
|
| Reoperation | 5 | 2018 | 4201 | 0.150 |
Why?
|
| Osteosarcoma | 2 | 2020 | 881 | 0.150 |
Why?
|
| Lumbosacral Region | 1 | 2019 | 310 | 0.150 |
Why?
|
| Female | 53 | 2020 | 380194 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2020 | 361 | 0.150 |
Why?
|
| Platelet Aggregation | 1 | 2020 | 798 | 0.150 |
Why?
|
| Humeral Head | 1 | 2017 | 41 | 0.150 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 116 | 0.150 |
Why?
|
| Nomograms | 2 | 2016 | 228 | 0.150 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 13102 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2019 | 319 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 2337 | 0.140 |
Why?
|
| Leg Bones | 1 | 2016 | 19 | 0.140 |
Why?
|
| Polymers | 2 | 2019 | 1621 | 0.140 |
Why?
|
| Muramidase | 2 | 2006 | 174 | 0.140 |
Why?
|
| Biomedical Technology | 1 | 2019 | 220 | 0.140 |
Why?
|
| Humerus | 1 | 2018 | 266 | 0.140 |
Why?
|
| Mobility Limitation | 1 | 2020 | 409 | 0.140 |
Why?
|
| Myocardial Revascularization | 1 | 2020 | 841 | 0.140 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 281 | 0.140 |
Why?
|
| Serum Albumin | 2 | 2017 | 676 | 0.140 |
Why?
|
| Silicon | 2 | 2006 | 145 | 0.140 |
Why?
|
| Adult | 36 | 2023 | 214055 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2019 | 1014 | 0.130 |
Why?
|
| Prognosis | 13 | 2023 | 29063 | 0.130 |
Why?
|
| Ligaments, Articular | 1 | 2018 | 298 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 2948 | 0.130 |
Why?
|
| RNA Viruses | 2 | 2007 | 124 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 865 | 0.130 |
Why?
|
| Amides | 3 | 2007 | 459 | 0.130 |
Why?
|
| Multiple Trauma | 1 | 2018 | 367 | 0.130 |
Why?
|
| Risk Factors | 17 | 2021 | 72290 | 0.130 |
Why?
|
| Computer Simulation | 8 | 2008 | 6196 | 0.130 |
Why?
|
| Membranes, Artificial | 2 | 2006 | 378 | 0.130 |
Why?
|
| Fractures, Bone | 2 | 2018 | 1947 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2017 | 370 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2017 | 305 | 0.120 |
Why?
|
| Pelvic Bones | 1 | 2016 | 265 | 0.120 |
Why?
|
| Antitubercular Agents | 3 | 2007 | 1320 | 0.120 |
Why?
|
| Coronary Stenosis | 1 | 2020 | 834 | 0.120 |
Why?
|
| Thymosin | 1 | 2013 | 47 | 0.120 |
Why?
|
| Patient Selection | 4 | 2020 | 4215 | 0.110 |
Why?
|
| Drug Delivery Systems | 3 | 2019 | 2219 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 3143 | 0.110 |
Why?
|
| Orthopedics | 1 | 2022 | 904 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2017 | 290 | 0.110 |
Why?
|
| Mortality | 3 | 2020 | 2864 | 0.110 |
Why?
|
| Humeral Fractures | 1 | 2015 | 272 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2019 | 1530 | 0.110 |
Why?
|
| Survival Rate | 7 | 2020 | 12788 | 0.110 |
Why?
|
| Femoral Fractures | 1 | 2016 | 376 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2012 | 154 | 0.100 |
Why?
|
| Antifungal Agents | 2 | 2007 | 730 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 4262 | 0.100 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2017 | 591 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 85 | 0.100 |
Why?
|
| Molecular Structure | 8 | 2007 | 1899 | 0.100 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 57776 | 0.100 |
Why?
|
| Internationality | 1 | 2017 | 1003 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2023 | 15540 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2016 | 969 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 608 | 0.090 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 1965 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2015 | 775 | 0.090 |
Why?
|
| Awards and Prizes | 1 | 2015 | 375 | 0.090 |
Why?
|
| Imidazoles | 2 | 2007 | 1206 | 0.090 |
Why?
|
| Joint Instability | 1 | 2018 | 792 | 0.090 |
Why?
|
| Leg | 1 | 2015 | 1116 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2017 | 3420 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2020 | 10252 | 0.090 |
Why?
|
| Models, Chemical | 3 | 2007 | 626 | 0.090 |
Why?
|
| RNA Helicases | 2 | 2007 | 142 | 0.090 |
Why?
|
| Neoplasm Metastasis | 5 | 2019 | 4851 | 0.090 |
Why?
|
| Angioplasty | 1 | 2012 | 364 | 0.090 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 13695 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2109 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 1956 | 0.090 |
Why?
|
| Athletes | 1 | 2017 | 1093 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1301 | 0.090 |
Why?
|
| Protein Precursors | 1 | 2013 | 1154 | 0.080 |
Why?
|
| England | 2 | 2021 | 522 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 3670 | 0.080 |
Why?
|
| Surgical Wound Infection | 2 | 2016 | 1540 | 0.080 |
Why?
|
| Time Factors | 9 | 2021 | 40075 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2015 | 1094 | 0.080 |
Why?
|
| Umbelliferones | 1 | 2007 | 12 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 21683 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 403 | 0.080 |
Why?
|
| Adenine Nucleotides | 1 | 2008 | 121 | 0.080 |
Why?
|
| Picornaviridae | 1 | 2007 | 23 | 0.080 |
Why?
|
| Carcinoma | 1 | 2019 | 2375 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6538 | 0.080 |
Why?
|
| Histones | 1 | 2018 | 2599 | 0.080 |
Why?
|
| Candida glabrata | 1 | 2007 | 34 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 3068 | 0.080 |
Why?
|
| Drug Design | 4 | 2008 | 1076 | 0.080 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 818 | 0.070 |
Why?
|
| Phenanthrolines | 1 | 2007 | 55 | 0.070 |
Why?
|
| Knee | 1 | 2009 | 274 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2727 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2007 | 1832 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 793 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1671 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 2006 | 1736 | 0.070 |
Why?
|
| Platelet Count | 2 | 2019 | 781 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 546 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2459 | 0.070 |
Why?
|
| Ischemia | 1 | 2015 | 1907 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2016 | 1329 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 2208 | 0.070 |
Why?
|
| Keto Acids | 1 | 2005 | 34 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2019 | 549 | 0.070 |
Why?
|
| Blotting, Southern | 1 | 2006 | 803 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 365 | 0.060 |
Why?
|
| Piperazines | 2 | 2006 | 2488 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8642 | 0.060 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 39050 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2503 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 1637 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2006 | 596 | 0.060 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2006 | 190 | 0.060 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 19905 | 0.060 |
Why?
|
| Structure-Activity Relationship | 5 | 2008 | 3129 | 0.060 |
Why?
|
| Candida albicans | 1 | 2007 | 394 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 854 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2017 | 5007 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 1873 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2019 | 4599 | 0.060 |
Why?
|
| Polyamines | 1 | 2004 | 120 | 0.060 |
Why?
|
| Phosphonoacetic Acid | 1 | 2003 | 55 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2011 | 1248 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2006 | 2942 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3887 | 0.060 |
Why?
|
| Young Adult | 10 | 2020 | 56430 | 0.060 |
Why?
|
| Cyclodextrins | 1 | 2003 | 57 | 0.060 |
Why?
|
| Contrast Media | 1 | 2017 | 5300 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 3798 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2017 | 3114 | 0.060 |
Why?
|
| Risk Assessment | 6 | 2020 | 23338 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 77 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 434 | 0.060 |
Why?
|
| Logistic Models | 4 | 2019 | 13408 | 0.060 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 1186 | 0.060 |
Why?
|
| Adolescent | 7 | 2020 | 85781 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 1723 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 2148 | 0.050 |
Why?
|
| Hemeproteins | 1 | 2002 | 62 | 0.050 |
Why?
|
| Bone Transplantation | 2 | 2018 | 907 | 0.050 |
Why?
|
| Esters | 1 | 2003 | 210 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 9959 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 776 | 0.050 |
Why?
|
| Protoporphyrins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Anxiety | 1 | 2016 | 4297 | 0.050 |
Why?
|
| Cohort Studies | 6 | 2022 | 40561 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2006 | 1063 | 0.050 |
Why?
|
| Hexokinase | 2 | 1992 | 125 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2018 | 1842 | 0.050 |
Why?
|
| Equipment Design | 2 | 2020 | 3582 | 0.050 |
Why?
|
| Nanostructures | 1 | 2006 | 551 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15076 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2014 | 2788 | 0.050 |
Why?
|
| Materials Testing | 2 | 2020 | 867 | 0.050 |
Why?
|
| Triazoles | 1 | 2006 | 911 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2005 | 689 | 0.050 |
Why?
|
| Models, Biological | 2 | 2006 | 9583 | 0.050 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 643 | 0.040 |
Why?
|
| Reference Values | 2 | 2017 | 4982 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 8949 | 0.040 |
Why?
|
| Colombia | 1 | 2020 | 258 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2004 | 693 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 319 | 0.040 |
Why?
|
| Lymphoma | 2 | 2019 | 1877 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 4 | 2007 | 3846 | 0.040 |
Why?
|
| Physicians | 1 | 2017 | 4567 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2020 | 270 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2021 | 886 | 0.040 |
Why?
|
| Albumins | 1 | 2021 | 569 | 0.040 |
Why?
|
| Mutation | 2 | 2018 | 29786 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2020 | 2925 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 1381 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 832 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2020 | 4577 | 0.040 |
Why?
|
| Necrosis | 1 | 2022 | 1643 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2016 | 12720 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5751 | 0.040 |
Why?
|
| Cell Line | 6 | 2008 | 15997 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2006 | 4011 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2005 | 1379 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11524 | 0.040 |
Why?
|
| Arthrodesis | 1 | 2019 | 189 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 2 | 2020 | 2657 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2020 | 961 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2003 | 1182 | 0.040 |
Why?
|
| Molecular Conformation | 3 | 2003 | 563 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3255 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 2728 | 0.040 |
Why?
|
| ROC Curve | 2 | 2017 | 3527 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2023 | 21746 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 339 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20129 | 0.040 |
Why?
|
| Sacrum | 1 | 2019 | 288 | 0.040 |
Why?
|
| Apoptosis | 1 | 2013 | 9727 | 0.040 |
Why?
|
| Climate Change | 1 | 2022 | 418 | 0.040 |
Why?
|
| Depression | 1 | 2016 | 7766 | 0.040 |
Why?
|
| Aftercare | 1 | 2023 | 866 | 0.040 |
Why?
|
| Folic Acid | 1 | 2003 | 1300 | 0.040 |
Why?
|
| Binding Sites | 4 | 2007 | 6114 | 0.030 |
Why?
|
| Fractures, Stress | 1 | 2018 | 187 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 435 | 0.030 |
Why?
|
| Radiography | 2 | 2019 | 7023 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2006 | 8436 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2282 | 0.030 |
Why?
|
| Embolism, Fat | 1 | 2015 | 47 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 2216 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2022 | 817 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2012 | 1770 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2019 | 9849 | 0.030 |
Why?
|
| Patients | 1 | 2022 | 900 | 0.030 |
Why?
|
| Fracture Fixation | 1 | 2017 | 354 | 0.030 |
Why?
|
| Artificial Limbs | 1 | 2016 | 123 | 0.030 |
Why?
|
| Fracture Healing | 1 | 2017 | 427 | 0.030 |
Why?
|
| Morbidity | 1 | 2020 | 1769 | 0.030 |
Why?
|
| Posture | 1 | 2019 | 958 | 0.030 |
Why?
|
| Pelvis | 1 | 2019 | 730 | 0.030 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 2376 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 2019 | 594 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2016 | 156 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2006 | 459 | 0.030 |
Why?
|
| Cricetinae | 2 | 2008 | 2472 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 977 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2023 | 35421 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 2618 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 1654 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2023 | 1922 | 0.030 |
Why?
|
| Models, Animal | 1 | 2020 | 2171 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 1094 | 0.030 |
Why?
|
| Hexosephosphates | 1 | 1992 | 26 | 0.030 |
Why?
|
| Cell Survival | 3 | 2007 | 5882 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2018 | 819 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20822 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2309 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 1585 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 1578 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 2879 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 675 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2007 | 1877 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 2924 | 0.020 |
Why?
|
| Protein Transport | 2 | 2006 | 1988 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2017 | 1534 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 5181 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2017 | 1533 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12354 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 2017 | 695 | 0.020 |
Why?
|
| Benzamides | 2 | 2006 | 1379 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3313 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 1239 | 0.020 |
Why?
|
| Swine | 1 | 2020 | 5917 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 551 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4186 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2008 | 2203 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2016 | 1827 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 5535 | 0.020 |
Why?
|
| Observer Variation | 1 | 2015 | 2593 | 0.020 |
Why?
|
| Diarrhea Viruses, Bovine Viral | 1 | 2008 | 6 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 7729 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 96 | 0.020 |
Why?
|
| Aspirin | 1 | 2020 | 3282 | 0.020 |
Why?
|
| Mannich Bases | 1 | 2007 | 3 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2008 | 223 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 4776 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 2009 | 309 | 0.020 |
Why?
|
| Prevalence | 2 | 2017 | 15226 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2012 | 648 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 215 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1184 | 0.020 |
Why?
|
| Entropy | 1 | 2008 | 209 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2012 | 1074 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 462 | 0.020 |
Why?
|
| Enterovirus | 1 | 2007 | 64 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
| Magnesium Hydroxide | 1 | 2006 | 10 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8324 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
| Adsorption | 1 | 2006 | 201 | 0.020 |
Why?
|
| Aluminum Hydroxide | 1 | 2006 | 58 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2008 | 3760 | 0.020 |
Why?
|
| Animals | 7 | 2020 | 168757 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 882 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 503 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2007 | 241 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2007 | 1157 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2005 | 29 | 0.020 |
Why?
|
| Isoleucine | 1 | 2005 | 112 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 1848 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1359 | 0.020 |
Why?
|
| Candida | 1 | 2006 | 172 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 730 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2009 | 607 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 419 | 0.020 |
Why?
|
| Diffusion | 1 | 2006 | 833 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 454 | 0.020 |
Why?
|
| Threonine | 1 | 2005 | 279 | 0.020 |
Why?
|
| Kidney | 1 | 2020 | 7186 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 6386 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11366 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2019 | 5102 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 1541 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2012 | 1640 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 2003 | 156 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4253 | 0.010 |
Why?
|
| Pneumonia | 1 | 2015 | 2133 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 2003 | 518 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12959 | 0.010 |
Why?
|
| Health Status | 1 | 2016 | 4034 | 0.010 |
Why?
|
| Solvents | 1 | 2004 | 302 | 0.010 |
Why?
|
| Nucleosides | 1 | 2003 | 138 | 0.010 |
Why?
|
| Dogs | 1 | 2007 | 3912 | 0.010 |
Why?
|
| Escherichia coli | 2 | 1992 | 4217 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2014 | 3086 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 1375 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 6895 | 0.010 |
Why?
|
| Child | 2 | 2020 | 77709 | 0.010 |
Why?
|
| Cattle | 1 | 2008 | 3922 | 0.010 |
Why?
|
| Wound Healing | 1 | 2012 | 2785 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2002 | 201 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
| Surface Properties | 1 | 2004 | 1184 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 8340 | 0.010 |
Why?
|
| Thiazoles | 1 | 2008 | 1483 | 0.010 |
Why?
|
| Myocardium | 1 | 2013 | 4776 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 3479 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2014 | 6442 | 0.010 |
Why?
|
| Ligands | 1 | 2007 | 3282 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 1454 | 0.010 |
Why?
|
| Registries | 1 | 2015 | 8089 | 0.010 |
Why?
|
| Age Factors | 1 | 2016 | 18370 | 0.010 |
Why?
|
| Stroke | 2 | 2012 | 9981 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5985 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1992 | 1801 | 0.010 |
Why?
|
| Skin | 1 | 2012 | 4364 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1991 | 3848 | 0.010 |
Why?
|
| Proteins | 1 | 1991 | 6103 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 25043 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7913 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7279 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 9386 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4386 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 3521 | 0.010 |
Why?
|
| Placenta | 2 | 1992 | 1698 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1992 | 305 | 0.010 |
Why?
|
| Mice | 2 | 2013 | 81183 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 11727 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5172 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 4189 | 0.010 |
Why?
|
| Catalysis | 1 | 1992 | 761 | 0.010 |
Why?
|
| Base Sequence | 2 | 1992 | 12797 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1992 | 13815 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1991 | 1581 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1992 | 810 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1992 | 18111 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 1572 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 16689 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1992 | 3701 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 4320 | 0.000 |
Why?
|
| HIV-1 | 1 | 2003 | 6939 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1992 | 5179 | 0.000 |
Why?
|
| Kinetics | 1 | 1992 | 6473 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3870 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1992 | 6622 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 7301 | 0.000 |
Why?
|
| Pregnancy | 1 | 1992 | 29144 | 0.000 |
Why?
|